Corvus Pharmaceuticals, Inc. Increase (Decrease) in Accounts Receivable, Related Parties
Corvus Pharmaceuticals, Inc. (CRVS) reported Increase (Decrease) in Accounts Receivable, Related Parties of -$43.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties · last filed 2025-11-04
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2025-09-30 was -$54.00K, a 254.29% decline year-over-year.
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2025-06-30 was $7.00K.
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2025-03-31 was $4.00K.
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2024-12-31 was $5.00K, a 66.67% decline year-over-year.
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts receivable, related parties for fiscal 2024 was $49.00K.
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts receivable, related parties for fiscal 2023 was -$562.00K, a 793.83% decline from fiscal 2022.
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts receivable, related parties for fiscal 2022 was $81.00K, a 84.02% decline from fiscal 2021.
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts receivable, related parties for fiscal 2021 was $507.00K.
| Period end | Increase (Decrease) in Accounts Receivable, Related Parties 3 month | Increase (Decrease) in Accounts Receivable, Related Parties 6 month | Increase (Decrease) in Accounts Receivable, Related Parties 9 month | Increase (Decrease) in Accounts Receivable, Related Parties 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$47.00K derived: sum of 2 quarters · filed 2025-11-04 | -$43.00K 10-Q · filed 2025-11-04 | -$38.00K derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $11.00K 10-Q · filed 2025-08-07 | $16.00K derived: sum of 3 quarters · filed 2025-08-07 | $51.00K derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-03-31 | $4.00K 10-Q · filed 2025-05-08 | $9.00K derived: sum of 2 quarters · filed 2025-05-08 | $44.00K derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $40.00K derived: sum of 2 quarters · filed 2025-11-04 | $49.00K 10-K · filed 2025-03-25 | |
| 2024-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $44.00K 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $9.00K 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $26.00K derived: sum of 2 quarters · filed 2025-03-25 | -$403.00K derived: sum of 3 quarters · filed 2025-03-25 | -$562.00K 10-K · filed 2025-03-25 |
| 2023-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$418.00K derived: sum of 2 quarters · filed 2024-11-12 | -$577.00K 10-Q · filed 2024-11-12 | -$492.00K derived: sum of 4 quarters · filed 2025-03-25 |
| 2023-06-30 | -$429.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$588.00K 10-Q · filed 2024-08-06 | -$503.00K derived: sum of 3 quarters · filed 2025-03-25 | -$373.00K derived: sum of 4 quarters · filed 2025-03-25 |
| 2023-03-31 | -$159.00K 10-Q · filed 2024-05-07 | -$74.00K derived: sum of 2 quarters · filed 2025-03-25 | $56.00K derived: sum of 3 quarters · filed 2025-03-25 | $56.00K derived: sum of 4 quarters · filed 2025-03-25 |
| 2022-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $215.00K derived: sum of 2 quarters · filed 2025-03-25 | $215.00K derived: sum of 3 quarters · filed 2025-03-25 | $81.00K 10-K · filed 2025-03-25 |
| 2022-09-30 | $130.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $130.00K derived: sum of 2 quarters · filed 2023-11-07 | -$4.00K 10-Q · filed 2023-11-07 | $227.00K derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$134.00K 10-Q · filed 2023-08-08 | $97.00K derived: sum of 3 quarters · filed 2024-03-19 | $370.00K derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | -$134.00K 10-Q · filed 2023-05-08 | $97.00K derived: sum of 2 quarters · filed 2024-03-19 | $370.00K derived: sum of 3 quarters · filed 2024-03-19 | |
| 2021-12-31 | $231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $504.00K derived: sum of 2 quarters · filed 2024-03-19 | $507.00K 10-K · filed 2024-03-19 | |
| 2021-09-30 | $273.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $276.00K 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $3.00K 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |